Details:
Results from the study, comparing the two technology platforms at multiple doses, demonstrate that the mRNA and the protein vaccines were well tolerated and generated T cell and antibody responses.
Lead Product(s): mRNA-based HSV-2 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
ILB® to inhibit infection of human cells by four serotypes of Dengue virus (DENV1-4), two strains of Zika virus (African and Asian) and Yellow Fever virus (vaccine strain YF17D) assessed by immunofluorescence of viral particles.
Lead Product(s): LMW-dextran Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: ILB
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
ISR will have exclusive rights to use ICOone for treating Covid-19 and its variants with a technology based on spike proteins with an adjuvant. Iconovo will develop an inhalation product for the purpose of testing it in a human clinical trial.
Lead Product(s): Adjuvanted SARS-CoV-2 spike proteins
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Immune System Regulation
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Agreement April 01, 2021
Details:
Liverpool University with Keele University will study Tafoxiparin in order to find an effective treatment of patients who’ve been struck by COVID-19 virus.
Lead Product(s): Tafoxiparin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Liverpool University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 17, 2020
Details:
The vaccine is based on TCER AB's platform technology for the production of proteins and ISR's drug pipeline with immunostimulating immunolides.
Lead Product(s): Corona vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2020